231 related articles for article (PubMed ID: 37637209)
1. Targeting Duchenne muscular dystrophy by skipping DMD exon 45 with base editors.
Gapinske M; Winter J; Swami D; Gapinske L; Woods WS; Shirguppe S; Miskalis A; Busza A; Joulani D; Kao CJ; Kostan K; Bigot A; Bashir R; Perez-Pinera P
Mol Ther Nucleic Acids; 2023 Sep; 33():572-586. PubMed ID: 37637209
[TBL] [Abstract][Full Text] [Related]
2. Single-swap editing for the correction of common Duchenne muscular dystrophy mutations.
Chai AC; Chemello F; Li H; Nishiyama T; Chen K; Zhang Y; Sánchez-Ortiz E; Alomar A; Xu L; Liu N; Bassel-Duby R; Olson EN
Mol Ther Nucleic Acids; 2023 Jun; 32():522-535. PubMed ID: 37215149
[TBL] [Abstract][Full Text] [Related]
3. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
4. Gene modification strategies using AO-mediated exon skipping and CRISPR/Cas9 as potential therapies for Duchenne muscular dystrophy patients.
Solberg MH; Shariatzadeh M; Wilson SL
Eng Biol; 2020 Dec; 4(3):37-42. PubMed ID: 36968157
[TBL] [Abstract][Full Text] [Related]
5. Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells.
Ifuku M; Iwabuchi KA; Tanaka M; Lung MSY; Hotta A
Methods Mol Biol; 2018; 1828():191-217. PubMed ID: 30171543
[TBL] [Abstract][Full Text] [Related]
6. Correction of DMD in human iPSC-derived cardiomyocytes by base-editing-induced exon skipping.
Wang P; Li H; Zhu M; Han RY; Guo S; Han R
Mol Ther Methods Clin Dev; 2023 Mar; 28():40-50. PubMed ID: 36588820
[TBL] [Abstract][Full Text] [Related]
7. A consolidated AAV system for single-cut CRISPR correction of a common Duchenne muscular dystrophy mutation.
Zhang Y; Nishiyama T; Li H; Huang J; Atmanli A; Sanchez-Ortiz E; Wang Z; Mireault AA; Mammen PPA; Bassel-Duby R; Olson EN
Mol Ther Methods Clin Dev; 2021 Sep; 22():122-132. PubMed ID: 34485599
[TBL] [Abstract][Full Text] [Related]
8. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
[TBL] [Abstract][Full Text] [Related]
9. Prevention of early-onset cardiomyopathy in
Rok M; Wong TWY; Maino E; Ahmed A; Yang G; Hyatt E; Lindsay K; Fatehi S; Marks R; Delgado-Olguín P; Ivakine EA; Cohn RD
Mol Ther Methods Clin Dev; 2023 Sep; 30():246-258. PubMed ID: 37545481
[TBL] [Abstract][Full Text] [Related]
10. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing.
Chemello F; Chai AC; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Atmanli A; Mireault AA; Liu N; Bassel-Duby R; Olson EN
Sci Adv; 2021 Apr; 7(18):. PubMed ID: 33931459
[TBL] [Abstract][Full Text] [Related]
11. CRISPR Therapeutics for Duchenne Muscular Dystrophy.
Erkut E; Yokota T
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163754
[TBL] [Abstract][Full Text] [Related]
12. A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing.
Zhang Y; Li H; Nishiyama T; McAnally JR; Sanchez-Ortiz E; Huang J; Mammen PPA; Bassel-Duby R; Olson EN
Mol Ther Nucleic Acids; 2022 Sep; 29():525-537. PubMed ID: 36035749
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.
Li J; Wang K; Zhang Y; Qi T; Yuan J; Zhang L; Qiu H; Wang J; Yang HT; Dai Y; Song Y; Chang X
Circulation; 2021 Nov; 144(22):1760-1776. PubMed ID: 34698513
[TBL] [Abstract][Full Text] [Related]
14. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing.
Aslesh T; Erkut E; Yokota T
Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973
[No Abstract] [Full Text] [Related]
15. Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing.
Long C; Li H; Tiburcy M; Rodriguez-Caycedo C; Kyrychenko V; Zhou H; Zhang Y; Min YL; Shelton JM; Mammen PPA; Liaw NY; Zimmermann WH; Bassel-Duby R; Schneider JW; Olson EN
Sci Adv; 2018 Jan; 4(1):eaap9004. PubMed ID: 29404407
[TBL] [Abstract][Full Text] [Related]
16. Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy.
Lim KRQ; Yoon C; Yokota T
J Pers Med; 2018 Nov; 8(4):. PubMed ID: 30477208
[TBL] [Abstract][Full Text] [Related]
17. Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy.
Mollanoori H; Rahmati Y; Hassani B; Havasi Mehr M; Teimourian S
Genes Dis; 2021 Mar; 8(2):146-156. PubMed ID: 33997161
[TBL] [Abstract][Full Text] [Related]
18. Efficient exon skipping by base-editor-mediated abrogation of exonic splicing enhancers.
Qiu H; Li G; Yuan J; Yang D; Ma Y; Wang F; Dai Y; Chang X
Cell Rep; 2023 Nov; 42(11):113340. PubMed ID: 37906593
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human
Egorova TV; Zotova ED; Reshetov DA; Polikarpova AV; Vassilieva SG; Vlodavets DV; Gavrilov AA; Ulianov SV; Buchman VL; Deykin AV
Dis Model Mech; 2019 Apr; 12(4):. PubMed ID: 31028078
[TBL] [Abstract][Full Text] [Related]
20. New advancements in CRISPR based gene therapy of Duchenne muscular dystrophy.
Eslahi A; Alizadeh F; Avan A; Ferns GA; Moghbeli M; Reza Abbaszadegan M; Mojarrad M
Gene; 2023 May; 867():147358. PubMed ID: 36914142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
